Skip to Content

Helix Biomedix Inc HXBM

Morningstar Rating
$23.27 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HXBM is trading at a 3% discount.
Price
$23.26
Fair Value
$37.91
Uncertainty
Extreme
1-Star Price
$469.35
5-Star Price
$4.49
Economic Moat
Bsgjrg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HXBM is a good fit for your portfolio.

Trading Information

Previous Close Price
$23.27
Day Range
$23.2523.27
52-Week Range
$23.0023.36
Bid/Ask
$18.00 / $26.00
Market Cap
$3.86 Mil
Volume/Avg
400 / 190

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Helix Biomedix Inc is a specialty dermatology and consumer products skin health company with an extensive library of structurally diverse bioactive peptides and patents. The company's intellectual property portfolio offers multiple pathways for commercialization in the area ranging from Rx dermatology to aesthetic dermatology and personal care.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
8

Valuation

Metric
HXBM
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
HXBM
Quick Ratio
1.18
Current Ratio
2.33
Interest Coverage
Quick Ratio
No chart available

Profitability

Metric
HXBM
Return on Assets (Normalized)
−91.58%
Return on Equity (Normalized)
−109.58%
Return on Invested Capital (Normalized)
−109.64%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXfzf$550.2 Bil
VRTX
Vertex Pharmaceuticals IncVcgjs$111.1 Bil
REGN
Regeneron Pharmaceuticals IncSfdmnf$107.7 Bil
MRNA
Moderna IncRdtk$36.9 Bil
ARGX
argenx SE ADRGgqt$24.2 Bil
BNTX
BioNTech SE ADRKpb$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncGnknm$19.9 Bil
BMRN
Biomarin Pharmaceutical IncTsclqy$17.2 Bil
RPRX
Royalty Pharma PLC Class AKbhdxg$13.9 Bil
INCY
Incyte CorpCxfjxn$13.6 Bil

Sponsor Center